Two phase 3 trials of gantenerumab in early Alzheimer's disease
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer's disease. METHODS: We conducted two phase 3 trials (GRADUATE I and II) involving participants 50 to 90 years of age with mild cognitive impairment or mild dementia due to Alzheimer's disease and evidence of amyloid plaques on positron-emission tomography (PET) or cerebrospinal fluid (CSF) testing. Participants were randomly assigned to receive gantenerumab or placebo every 2 weeks. The primary outcome was the change from baseline in the score on the Clinical Dementia Rating scale-Sum of Boxes (CDR-SB; range, 0 to 18, with higher scores indicating greater cognitive impairment) at week 116. RESULTS: A total of 985 and 980 participants were enrolled in the GRADUATE I and II trials, respectively. The baseline CDR-SB score was 3.7 in the GRADUATE I trial and 3.6 in the GRADUATE II trial. The change from baseline in the CDR-SB score at week 116 was 3.35 with gantenerumab and 3.65 with placebo in the GRADUATE I trial (difference, -0.31; 95% confidence interval [CI], -0.66 to 0.05; P = 0.10) and was 2.82 with gantenerumab and 3.01 with placebo in the GRADUATE II trial (difference, -0.19; 95% CI, -0.55 to 0.17; P = 0.30). At week 116, the difference in the amyloid level on PET between the gantenerumab group and the placebo group was -66.44 and -56.46 centiloids in the GRADUATE I and II trials, respectively, and amyloid-negative status was attained in 28.0% and 26.8% of the participants receiving gantenerumab in the two trials. Across both trials, participants receiving gantenerumab had lower CSF levels of phosphorylated tau 181 and higher levels of Aβ42 than those receiving placebo; the accumulation of aggregated tau on PET was similar in the two groups. Amyloid-related imaging abnormalities with edema (ARIA-E) occurred in 24.9% of the participants receiving gantenerumab, and symptomatic ARIA-E occurred in 5.0%. CONCLUSIONS: Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline. (Funded by F. Hoffmann-La Roche; GRADUATE I and II ClinicalTrials.gov numbers, NCT03444870 and NCT03443973, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two phase III trials (NCT03444870 and NCT03443973) were recently terminated. In these trials, when assessing the efficacy and safety of gantenerumab (19) in participants with early (prodromal to mild) AD, the drug showed little clinical benefit in slowing cognitive decline, potentially due to limited clearance of amyloid plaques, with 5.0% participants experienced amyloid-related imaging abnormal”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [461]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationDonanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Self-citation
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Self-citationZhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
Dubois, B., Villain, N., Schneider, L., Fox, N., Campbell, N., Galasko, D., Kivipelto, M., Jessen, F., Hanseeuw, B., Boada, M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3770 · Cited by 426
Self-citationZimmer, J. A., Ardayfio, P., Wang, H., Khanna, R., Evans, C. D., Lu, M., Sparks, J., Andersen, S., Lauzon, S., Nery, E. S. M., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0065 · Cited by 168
Self-citationKim, B., Kim, S., Nam, Y., Park, Y., Shin, S. M., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00465-w · Cited by 187
Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium
Collij, L. E., Bollack, A., Joie, R. L., Shekari, M., Bullich, S., Roé-Vellvé, N., Koglin, N., Jovalekic, A., García, D. V., Drzezga, A. E., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14336 · Cited by 138
Crossing the blood–brain barrier: emerging therapeutic strategies for neurological disease
Pedder, J. H., Sonabend, A. M., Cearns, M. D., Michael, B. D., Zakaria, R., Heimberger, A. B., Jenkinson, M. D., & Dickens, D. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00476-9 · Cited by 127
Liu, S., Jin, X., Ge, Y., Dong, J., Liu, X., Pei, X., Wang, P., Wang, B., Chang, Y., & Yu, X. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03415-w · Cited by 127
“The bispecific antibody gantenerumab (anti-TfR/anti-Aβ) showed enhanced amyloid plaque reduction in Phase III Alzheimer’s trials (NCT03444870 and NCT03443973) though cognitive benefits remain limited [152].”
Avgerinos, K. I., Manolopoulos, A., Ferrucci, L., & Kapogiannis, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-75204-8 · Cited by 95
“1) 4–6 ,22–30 .”
InfluentialCummings, J. L. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00570 · Cited by 94
“Reactions were typically mild [39].”
Self-citationVillain, N., Planche, V., Lilamand, M., Cordonnier, C., Soto‐Martin, M., Mollion, H., Bombois, S., & Delrieu, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100094 · Cited by 95
“The aducanumab and gantenerumab phase 3 clinical trials excluded patients on anticoagulants [ 64 , 90 ].”
Belder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., Barkhof, F., & Fox, N. C. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00335-1 · Cited by 85
Self-citationModified titration of donanemab reduces ARIA risk and maintains amyloid reduction
Wang, H., Nery, E. S. M., Ardayfio, P. A., Khanna, R., Svaldi, D. O., Gueorguieva, I., Shcherbinin, S., Andersen, S. W., Hauck, P. M., Engle, S. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70062 · Cited by 89
Self-citationSalloway, S., Wojtowicz, J., Voyle, N., Lane, C., Klein, G., Lyons, M., Rossomanno, S., Mazzo, F., Bullain, S., Barkhof, F., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3937 · Cited by 71
Self-citationA practical overview of the use of amyloid-PET Centiloid values in clinical trials and research
Iaccarino, L., Burnham, S. C., Tunali, I., Wang, J., Navitsky, M. A., Arora, A., & Pontecorvo, M. J. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103765 · Cited by 74
Bateman, R. J., Li, Y., McDade, E., Llibre‐Guerra, J. J., Clifford, D. B., Atri, A., Mills, S. L., Santacruz, A. M., Wang, G., Supnet, C. B., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00024-9 · Cited by 84
Self-citationBiomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 88
“Trials in which this threshold was achieved demonstrated slowing of decline whereas those that did not reduce Aβ plaque levels below this threshold showed no benefit 188,189 .”
Self-citationAlzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Manap, A. S. A., Almadodi, R., Sultana, S., Sebastian, M. G., Kavani, K. S., Lyenouq, V. E., & Shankar, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1429211 · Cited by 84
Söderberg, L., Johannesson, M., Gkanatsiou, E., Nygren, P., Fritz, N., Zachrisson, O., Rachalski, A., Svensson, A.-S., Button, E. B., Dentoni, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61691-2 · Cited by 71
Insights into the use of biomarkers in clinical trials in Alzheimer's disease
Pascoal, T. A., Aguzzoli, C. S., Lussier, F. Z., Crivelli, L., Suemoto, C. K., Fortea, J., Rosa‐Neto, P., Zimmer, E. R., Ferreira, P. C. L., & Bellaver, B. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105322 · Cited by 67
“17 Changes in biomarkers that indicate distant pathologies in the causal pathway of clinical symptoms, such as A β , are known to have the potential to produce con fl icting conclusions about clinical bene fi t. 106,107 This may be attributed to the fact that symptomatic patients already present…”
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions
Rafii, M. S., & Aisen, P. S. S. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01123-5 · Cited by 73
“The change in the GRADUATE II trial was 2.82 for the gantenerumab group and 3.01 for the placebo group, yielding a difference of −0.19 (95% CI: −0.55 to 0.17; P = 0.30) 17 .”
InfluentialRecent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
“Additionally, gantenerumab [150–152] and crenezumab [92,147,149] were examined.”
BackgroundOverview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Weiner, M. W., Kanoria, S., Miller, M. J., Aisen, P. S. S., Beckett, L. A., Conti, C., Diaz, A., Flenniken, D., Green, R. C., Harvey, D. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14321 · Cited by 65
Restoring the epigenome in Alzheimer's disease: advancing HDAC inhibitors as therapeutic agents
Pereira, M. S., Cruz, M. T., Fortuna, A. C., & Bicker, J. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104052 · Cited by 49
Concordance Between Amyloid-PET Quantification and Real-World Visual Reads
Zeltzer, E., Schonhaut, D. R., Mundada, N. S., Blazhenets, G., Mejía, J. A., Soleimani‐Meigooni, D. N., Cho, H., Ranasinghe, K. G., Windon, C., Yadollahikhales, G., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2218 · Cited by 49
Bougea, A. M., & Gourzis, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164661 · Cited by 47
“After 12 and 18 months in the therapy group, lecanemab (target class: amyloid-β ) exhibits a substantial rise in CSF A β 42 [49].”
BackgroundHu, Y., Cho, M., Sachdev, P., Dage, J., Hendrix, S., Hansson, O., Bateman, R. J., & Hampel, H. (2024) · Med · doi:10.1016/j.medj.2024.08.004 · Cited by 42
Self-citationLecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease
Fertan, E., Lam, J. Y. L., Albertini, G., Dewilde, M., Wu, Y., Akingbade, O. E. S., Böken, D., English, E. A., Strooper, B. D., & Klenerman, D. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70086 · Cited by 47
“Meanwhile, Gantenerumab failed to achieve significant therapeutic success in clinical trials, 34 yet it is being re-branded as Trontinemab, which is coupled with a “brainshuttle” allowing higher blood–brain barrier penetration, 35 thus making the results on its aggregate binding characteristics…”
Biofluid biomarkers in Alzheimer’s disease and other neurodegenerative dementias
Zetterberg, H., & Bendlin, B. B. (2026) · Nature · doi:10.1038/s41586-025-10018-w · Cited by 59
“In anti-Aβ antibody trials for AD, slowed increases in CSF NfL suggest attenuated neurodegeneration.”
Detka, J., Płachtij, N., Strzelec, M., Manik, A., & Sałat, K. (2024) · Molecules · doi:10.3390/molecules29184354 · Cited by 42
Alzheimer disease seen through the lens of sex and gender
Castro‐Aldrete, L., Einsiedler, M., Martínková, J., Depypere, H. T., Ang, T. F. A., Mielke, M. M., Sindi, S., Eyre, H. A., Au, R., Dimech, A. S., et al. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01071-0 · Cited by 49
“…the aducanumab, lecanemab and donanemab trials that were not stratified by sex, participants with the lowest tau protein deposits showed the best treatment responses 211,212 and in the gantenerumab phase III trial, PET imaging showed that women had higher brain tau levels than men at baseline 197 .”
de Koning, L. A., Vazquez-Matias, D. A., Beaino, W., Vugts, D. J., van Dongen, G. A. M. S., van der Flier, W. M., Ries, M. G., van Vuurden, D. G., Vijverberg, E. G. B., & van de Giessen, E. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100204 · Cited by 49
“Potential mAb candidates have failed, possibly due to crossing the BBB in insufficient quantities to exert a therapeutic effect [ 9 , 10 ].”
Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 46
“ARIAs were reported in clinical trials investigating the safety and efficacy of almost all mAbs, generally dose-dependent [115–117].”
BackgroundJeong, S. Y., Suh, C. H., Lim, J.-S., Shim, W. H., Heo, H., Choi, Y., Kim, H. S., Kim, S. J., & Lee, J.-H. (2025) · Neurology · doi:10.1212/wnl.0000000000213483 · Cited by 36
Nonino, F., Minozzi, S., Sambati, L., Del Giovane, C., Baldin, E., Bassi, M. C., De Santis, C., Gonzalez-Lorenzo, M., Vignatelli, L., Filippini, G., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016297 · Cited by 35
The Amyloid Cascade Hypothesis
Castellani, R. J., Jamshidi, P., Plascencia‐Villa, G., & Perry, G. L. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.10.014 · Cited by 46
Aisen, P. S. S., Bateman, R. J., Crowther, D. C., Cummings, J., Dwyer, J. R., Iwatsubo, T., Kosco‐Vilbois, M. H., McDade, E., Mohs, R. C., Scheltens, P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14342 · Cited by 38
“…AD that demonstrated (1) those individuals with the most robustamyloidreduction(“responders”)hadevidenceofclinical,cognitive,andbiomarkerbenefit, 37 and(2)asymptomaticindividualstreated for the longest period with gantenerumab may have an up to 50% reduction in the risk of developing dementia.”
Self-citationJoie, R. L., Cummings, J. L., Dage, J. L., Galasko, D. R., Ikonomović, M. D., Karikari, T. K., Landau, S. M., Llibre‐Guerra, J. J., Mummery, C. J., Ossenkoppele, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70997 · Cited by 38
Self-citationThe Impact of Anti-Amyloid Immunotherapies on Stroke Care
Bilodeau, P., Dickson, J. R., & Kozberg, M. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051245 · Cited by 33
“Of note, other anti-amyloid immunotherapies discussed in this review have shown either a lack of A β clearance or lower than expected A β clearance, and the trials of these antibodies failed to show clinical benefit [6–11].”
BackgroundRecent Insights into the Neurobiology of Alzheimer’s Disease and Advanced Treatment Strategies
Anitha, K., Singh, M. K., Kohat, K., Varshini, T. S., Chenchula, S., Padmavathi, R., Amerneni, L. S., Vishnu Vardhan, K., Mythili Bai, K., Chavan, M. R., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04384-1 · Cited by 42
Onisiforou, A., Charalambous, E. G., & Zanos, P. (2025) · Microorganisms · doi:10.3390/microorganisms13010090 · Cited by 36
“Similarly, Gantenerumab, another amyloid-removing drug reported at the Clinical Trials on AD (CTAD) conference, reduced amyloid plaque burden but failed to slow clinical progression [6].”
Jin, M., & Noble, J. M. (2024) · eNeuro · doi:10.1523/eneuro.0088-24.2024 · Cited by 39
Bio–Nano Toolbox for Precision Alzheimer's Disease Gene Therapy
Liu, Y., Xia, X., Zheng, M., & Shi, B. (2024) · Advanced Materials · doi:10.1002/adma.202314354 · Cited by 40
Miller, R., Paquette, J. D., Barker, A., Sapp, E., McHugh, N., Bramato, B. M., Yamada, N., Alterman, J. F., Echeverria, D., Yamada, K., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102359 · Cited by 30
“While numerous clinical trials involving ASOs in the CNS have been halted due to toxicity 4,19 and an inability to reach effective levels, 5,63 – 68 others have resulted in the development of disease-modifying drugs that change the lives of thousands of patients.”
Bispecific brain-penetrant antibodies for treatment of Alzheimer’s disease
Sehlin, D., Hultqvist, G., Michno, W., Aguilar, X., Dahlén, A. D., Cerilli, E., Bucher, N. M., van den Broek, S. L., & Syvänen, S. (2025) · The journal of prevention of Alzheimer's disease · doi:10.1016/j.tjpad.2025.100214 · Cited by 30
Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials
Abanto, J. T., Dwivedi, A. K., Imbimbo, B. P., & Espay, A. J. (2024) · Brain · doi:10.1093/brain/awae216 · Cited by 39
Tonegawa‐Kuji, R., Hou, Y., Hu, B., Lorincz‐Comi, N. J., Pieper, A. A., Tousi, B., Leverenz, J. B., & Cheng, F. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004568 · Cited by 36
“We also included the latest trial results for donanemab and gantenerumab [4,13].”
InfluentialAbushakra, S. R., Porsteinsson, A. P., Sabbagh, M., Watson, D., Power, A., Liang, E., MacSweeney, E., Boada, M., Flint, S., McLaine, R., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12498 · Cited by 41
Self-citationFang, S., Zhang, K., Liu, D., Yang, Y., Hu, X., Xie, W., Diao, K., Rao, Z., Wang, D., & Yang, W. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1408620 · Cited by 29
Vaghari, D., Mohankumar, G., Tan, K., Lowe, A., Shering, C., Tiňo, P., & Kourtzi, Z. (2025) · Nature Communications · doi:10.1038/s41467-025-61355-3 · Cited by 31
“Further, including patients who have progressed to advanced disease stages may reduce the potential of targets (e.g., amyloid removal targets) to be effective 3,15 – 17 .”
A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00872-7 · Cited by 32
“Trontinemab incorporates the same paratopes as gantenerumab – an antibody that failed to meet its primary endpoint in two Phase 3 trials, but slowly cleared amyloid and showed positive trends on several clinical outcomes [33].”
Vukmir, R. B. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52042 · Cited by 28
“30 They will conclude the ENVISION Study, the Phase IV post marketing evaluation, but will continue to advance the science and care in this area.”
The role of macrophage plasticity in neurodegenerative diseases
Ma, H., Zhu, M., Chen, M., Li, X., & Feng, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00624-7 · Cited by 25
“Nevertheless, the former group did not delay the progression of AD [202].”
BackgroundBiomarker treatment effects in two phase 3 trials of gantenerumab
Bittner, T., Tonietto, M., Klein, G., Belusov, A., Illiano, V. P., Voyle, N., Delmar, P., Scelsi, M. A., Gobbi, S., Silvestri, E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14414 · Cited by 25
“At 5).”
Self-citationNew and emerging drug therapies for Alzheimer disease
Waite, L. M. (2024) · Australian Prescriber · doi:10.18773/austprescr.2024.021 · Cited by 34
“14 Therefore, although amyloid removal was effective in prodromal disease, there was no impact on cognition.”
BackgroundAljuhani, M., Ashraf, A., & Edison, P. (2024) · Brain Communications · doi:10.1093/braincomms/fcae435 · Cited by 26
Nrf2/Bach1 signaling axis: A promising multifaceted therapeutic strategy for Alzheimer's disease
Soni, P., Sharma, S. M., Pieper, A. A., Paul, B. D., & Thomas, B. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00586 · Cited by 25
Amro, Z., Collins‐Praino, L. E., & Yool, A. J. (2024) · Bioscience Reports · doi:10.1042/bsr20231725 · Cited by 20
Cerebrospinal fluid proteomics identification of biomarkers for amyloid and tau PET stages
Wang, Z., Chen, Y., Gong, K., Zhao, B., Ning, Y., Chen, M., Li, Y., Ali, M., Timsina, J., Liu, M., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102031 · Cited by 31
Chhabra, A., Solanki, S., Saravanabawan, P., Venkiteswaran, A., Nimmathota, N., & Modi, N. M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2416947 · Cited by 26
“However, according to the more recent GRADUATE I and II studies, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline [44].”
Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer’s Disease
Zhang, B., Li, Y., Li, H., Shen, X., & Zhu, Z. (2025) · Brain Sciences · doi:10.3390/brainsci15101101 · Cited by 22
“Early immunotherapy attempts faced safety and efficacy limitations [28–33].”
InfluentialRecent Advances in Antibody Therapy for Alzheimer’s Disease: Focus on Bispecific Antibodies
Yang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136271 · Cited by 21
Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer’s Disease
Yoon, C. H., Groff, C., & Criss, O. (2024) · INNOVATIONS in pharmacy · doi:10.24926/iip.v15i1.5787 · Cited by 21
The Role of Amyloid- and Tau PET in the New Era of Alzheimer Disease Therapies
Chiotis, K., Wang, Y., Joie, R. L., & Rabinovici, G. D. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268339 · Cited by 26
Chaubey, K., Vázquez‐Rosa, E., Tripathi, S. J., Shin, M., Yu, Y., Dhar, M., Chakraborty, S., Yamakawa, M., Wang, X., Sridharan, P. S., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102535 · Cited by 32
Azargoonjahromi, A. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae066 · Cited by 20
Wang, Q., Chen, S., Wang, J., Shang, H., & Chen, X. (2024) · Brain Sciences · doi:10.3390/brainsci14100990 · Cited by 23
The Alzheimer's Disease Neuroimaging Initiative Neuropathology Core: An update
Perrin, R. J., Franklin, E. E., Bernhardt, H., Burns, A., Schwetye, K. E., Cairns, N. J., Baxter, M., Weiner, M. W., Morris, J. C., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14253 · Cited by 22
Qi, X., Nizamutdinov, D., Yi, S. S., Wu, E., & Huang, J. H. (2024) · Biomedicines · doi:10.3390/biomedicines12112636 · Cited by 19
Mulumba, J., Duan, R., Luo, B., Wu, J., Sulaiman, M., Wang, F., & Yang, Y. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.100675 · Cited by 25
Chundu, U. C., Thiriveedhi, S. R., Bhatti, C., Mupparaju, J. S., Otinashvili, N., & Gelishvili, E. (2025) · Cureus · doi:10.7759/cureus.85377 · Cited by 17
Coupled sleep rhythm disruption predicts cognitive decline in Alzheimer’s disease
Wei, T., Zhou, J., Wang, Z., Liu, X., Mi, Y., Zhao, Y., Xing, Y., Zhao, B., Zhou, S., Liu, Y., et al. (2025) · 中国科学通报:英文版 · doi:10.1016/j.scib.2025.03.023 · Cited by 22
Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets
Gu, X., Long, Q., Qi, Q., Zhou, J., Chen, S., & Wang, L. (2024) · BioScience Trends · doi:10.5582/bst.2023.01288 · Cited by 19
Rodent Models of Alzheimer’s Disease: Past Misconceptions and Future Prospects
Collins, H. M., & Greenfield, S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116222 · Cited by 21
“Nonetheless, A β -targeting drugs still routinely underperform in clinical trials in that they reduce amyloid burden but do not ameliorate cognitive deficits [117] and have not been shown to improve life expectancy [3,118].”
BackgroundTowards pharmacological prevention of Alzheimer disease
Llibre‐Guerra, J. J., McDade, E., Schindler, S. E., Clifford, D. B., Supnet, C. B., Atri, A., & Bateman, R. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01154-y · Cited by 20
Self-citationSerrano‐Pozo, A., Escott‐Price, V., Grinberg, L. T., Pascoal, T. A., Suárez‐Calvet, M., Dubois, B., & Sperling, R. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00198-4 · Cited by 21
Forlenza, O. V., & Barbosa, B. J. A. P. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2025-e001 · Cited by 22
Polypharmacology and Neuroprotective Effects of Gingerol in Alzheimer’s Disease
Priyadarshini, S., Goyal, K., Roopashree, R., Gupta, S. K., Roy, A., Biswas, R., Patra, S., Chauhan, P., Wadhwa, K., Singh, G., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04484-y · Cited by 17
Cerebral amyloid angiopathy: a narrative review
Noto, N. M., Speth, R. C., & Robison, L. S. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1632252 · Cited by 17
Anti-amyloid monoclonal antibody therapies in Alzheimer’s disease – a scoping review
Elamin, S. A., Shibli, A. N. A., Shaito, A. A., Al-Maadhadi, M., Zolezzi, M., & Pedersen, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.011 · Cited by 19
Long-acting nanomedicine for brain diseases
Liao, J., Huang, Q., Li, R., Gong, L., Li, T., & Lin, Z. X. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114665 · Cited by 31
Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid
Garcia‐Ratés, S., García‐Ayllón, M., Falgàs, N., Brangman, S. A., Esiri, M. M., Coen, C. W., & Greenfield, S. A. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13869 · Cited by 15
“43 Some clinicians do not feel that the clinical benefits outweigh the potential side effects associated with amyloid antibody medication, including the development of amyloidrelatedimagingabnormalities(ARIA).”
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Wicker, A., Shriram, J., Decourt, B., & Sabbagh, M. N. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00664-z · Cited by 18
“Bateman et al. [40] suggested that these results support he hypothesis that rapid plaque reduction to a level below the threshold of detection may be necessary to show clinical efficacy.”
BackgroundResultJeremic, D., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2025) · Journal of Medical Internet Research · doi:10.2196/68454 · Cited by 20
Kang, Y.-K., Min, J. W., Kwon, S. J., & Ha, S. (2025) · Tomography · doi:10.3390/tomography11080086 · Cited by 15
“…quantitative metric for amyloid PET, supporting amyloid positivity determination [27,28], disease progression prediction [29], amyloid burden increase monitoring [30], therapy candidate selection [14,15], treatment response evaluation [13,14,31,32], and treatment discontinuation decisions [14].”
Wang, H., Li, J., Tu, W., Wang, Z., Zhang, Y., Chang, L., Wu, Y., & Zhang, X. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240301 · Cited by 15
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
Ameen, T. B., Ali, U., Salma, O., Samee, M. A., Abbas, S. M. I., Kashif, S. N., Arifi, M. A., Ali, M., Khowaja, M., Ali, S. M. S., et al. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00968-3 · Cited by 22
“Unlike lecanemab (Aβ protofibrils) and donanemab (pyro-glutamate Aβ), gantenerumab did not demonstrate significant slowing of cognitive decline, suggesting that broad amyloid plaque reduction alone may lack clinical translatability [229, 230].”
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 16
Schreiner, T. G., Croitoru, C. G., Hodorog, D. N., & Cuciureanu, D. I. (2024) · Biomedicines · doi:10.3390/biomedicines12051096 · Cited by 15
“At the same time, Tau PET imaging showed no impact of the drug on Tau protein cerebral accumulation [66].”
BackgroundOrtiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala‐Tecuapetla, C., Carvajal, K., & Campos‐Peña, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010128 · Cited by 16
“…Mild to moderate AD, prodromal AD, participants at risk of memory loss III [197,198] Gantenerumab Mild AD, prodromal to mild AD, early AD III [123,199,200] Aducanumab Early AD III [201–203] Crenezumab Prodromal to mild AD III [204] Lecanemab Early AD, preclinical AD III [205] Donanemab Early…”
Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
Sha, S., Ren, L., Xing, X., Guo, W., Wang, Y., Li, Y., Cao, Y., & Qu, L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00846 · Cited by 19
Yang, Y., Diao, Y., Jiang, L., Li, F., Chen, L., Ni, M., Wang, Z., & Fang, H. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.018 · Cited by 11
“…(controversial due to mixed efficacy) 38,39 , lecanemab (showing promise) 40 , gantenerumab/solanezumab/bapi-neuzumab (ineffective in trials) 55 — 58 , crenezumab (well-tolerated but ineffective) 59 , valiltramiprosate (displaying potential benefits) 60,61 , and thonningianin A (effective…”
Scheltens, P., Atri, A., Feldman, H., Zetterberg, H., Sano, M., Johannsen, P., León, T., Bardtrum, L., Jeppesen, R., Hansen, C. T., et al. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70200 · Cited by 25
Self-citationde Havenon, A., Gottesman, R. F., Willamson, J. D., Rost, N. S., Sharma, R., Li, V., Littig, L., Stulberg, E. L., Falcone, G. J., Prabhakaran, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14126 · Cited by 13
Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns
Lu, D., Dou, F., & Gao, J. (2023) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2023.01215 · Cited by 14
Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials
Scott, I. A. (2024) · Age and Ageing · doi:10.1093/ageing/afae023 · Cited by 12
Metzendorf, N. G., Sehlin, D., & Hultqvist, G. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1645952 · Cited by 10
Geerts, H., Bergeler, S., Walker, M., Rose, R. H., & van der Graaf, P. H. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12474 · Cited by 14
“8 While it has been extensively documented that CSF A β 42 levels correlate inversely with central amyloid load in natural history progression, the impact of brain amyloid clearance by antibodies on changes in peripheral fluid A β levels is more complex.”
BackgroundMethodInfluentialTriumbari, E. K. A., Chiaravalloti, A., Schillaci, O., Mercuri, N. B., & Liguori, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240349 · Cited by 9
Kang, J., Son, Y., Yim, Y., Cho, H., Kim, J., Lark, A. R. S., Mir, F. A., Kim, H. J., Park, J., Lee, H., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.07.022 · Cited by 13
“Endogenous formaldehyde is normally excreted in urine [63].”
Metadata
- Authors
- Bateman, R. J., Smith, J., Donohue, M. C., Delmar, P., Abbas, R., Salloway, S., Wojtowicz, J., Blennow, K., Bittner, T., Black, S. E., Klein, G., Boada, M., Grimmer, T., Tamaoka, A., Perry, R. J., Turner, R. S., Watson, D., Woodward, M., Thanasopoulou, A., Lane, C., Baudler, M., Fox, N. C., Cummings, J. L., Fontoura, P., & Doody, R. S.
- Affiliations
- Washington University in St. Louis (US)
- Roche (United Kingdom) (GB)
- University of Southern California (US)
- F. Hoffmann-La Roche AG (CH)
- Brown University (US)
- Sahlgrenska University Hospital (SE)
- University of Toronto (CA)
- From the Department of Neurology, Washington University School of Medicine, St. Louis (R.J.B.); Roche Products, Welwyn Garden City (J.S., C.L.), and the Department of Brain Sciences, Faculty of Medicine, Imperial College London (R.J.P.), and the Dementia Research Centre, Department of Neurodegenerative Disease, and the U.K. Dementia Research Institute, Queen Square Institute of Neurology, University College London (N.C.F.), London — all in the United Kingdom; the Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego (M.C.D.), and Genentech, South San Francisco (T.B., R.S.D.) — both in California; F. Hoffmann–La Roche, Basel, Switzerland (P.D., R.A., J.W., T.B., G.K., A. Thanasopoulou, M. Baudler, P.F., R.S.D.); Butler Hospital and Warren Alpert Medical School, Brown University, Providence, RI (S.S.); the Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, and the Clinical Neurochemistry Laboratory, Sahlgrens...
- TUM Klinikum (DE)
- University of Tsukuba (JP)
- UCL Queen Square Institute of Neurology (GB)
- Georgetown University (US)
- Austin Hospital (AU)
- UK Dementia Research Institute (GB)
- University of Nevada, Las Vegas (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-11-16
- Volume
- 389
- Issue
- 20
- Pages
- 1862-1876
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10794000
- OpenAlex
- W4388688059
- Cited by
- 314
- References
- 30
- Citations by year
- 2026: 91 · 2025: 120 · 2024: 100 · 2023: 3
- FWCI
- 55.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- HAL (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- gantenerumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, mild cognitive impairment, mild dementia, amyloid PET, cerebrospinal fluid biomarkers, cognitive decline, treatment discontinuation, safety and tolerability, subcutaneous administration
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Antibodies, Monoclonal, Humans, Middle Aged, Amyloid beta-Peptides, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.